Overview
- The HHS Office for Civil Rights withdrew its September 2023 guidance that had outlined retail pharmacies’ civil-rights obligations to dispense certain reproductive-health medications, effective immediately.
- HHS said the prior guidance conflicted with policies in recent executive orders, including one enforcing the Hyde Amendment and directives to pull guidance not grounded in the agencies’ best reading of statutory authority.
- The rescission follows earlier litigation, including the 2023 State of Texas and Mayo Pharmacy case that favored pharmacy owners asserting conscience objections to dispensing abortion-related drugs.
- By removing the federal directive that treated refusal to dispense dual-use drugs such as methotrexate or misoprostol as potential discrimination, the change increases pharmacy discretion and could heighten access variability for patients.
- On the same day, the Justice Department and FDA asked a federal court in Louisiana to pause a lawsuit over FDA’s 2023 decision to drop in-person dispensing rules for mifepristone, citing an ongoing FDA safety review that the government argued may render the case unnecessary.